Protein sequencing

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Thursday, March 7, 2024

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232

Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • “We are pleased with our ability to launch the version 2 sequencing kit well within the previously provided timeline.
  • We have also released full year 2024 financial guidance.”
    During the fourth quarter of 2023, the Company continued its controlled commercial launch of its Platinum instrument, recording revenue of $400,000.
  • As of December 31, 2023, the Company’s cash and cash equivalents and investments in marketable securities were $257.7 million.

Quantum-Si to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Retrieved on: 
Friday, February 9, 2024

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.
  • Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.
  • Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call.
  • An archived webcast of the event will be available for replay following the event.

Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

Retrieved on: 
Monday, February 5, 2024

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits.
  • The recent launch marks an expansion of the Company's current Platinum applications, now incorporating peptide barcodes and accommodating new sample types.
  • “With this launch, Quantum-Si is set to deliver unparalleled insights into protein characterization and function, catering to the evolving needs of our diverse customer base.
  • In tandem with its recent announcement, the company’s CEO and executive team have released a video outlining recent enhancements.

Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

Retrieved on: 
Thursday, January 18, 2024

TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout Japan.

Key Points: 
  • TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout Japan.
  • “Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences.
  • We’re poised to empower Japanese researchers with cutting edge technology, fostering unparalleled discoveries,” said Kenjiro Tominaga, Owner, President and CEO of TOMY Digital Biology.
  • We believe that through TOMY's exceptional distribution capabilities and our groundbreaking technology, we will empower researchers in Japan to achieve new milestones in their scientific endeavors."

Quantum-Si Expands Global Reach with Addition of New Distributor

Retrieved on: 
Tuesday, December 12, 2023

3Genes Distribution a.s., a prominent technology provider specializing in life science and diagnostics in Eastern Europe will distribute Quantum-Si’s Platinum across the Czech Republic, Slovakia, and Hungary.

Key Points: 
  • 3Genes Distribution a.s., a prominent technology provider specializing in life science and diagnostics in Eastern Europe will distribute Quantum-Si’s Platinum across the Czech Republic, Slovakia, and Hungary.
  • "We are thrilled to welcome this esteemed distributor to our global network, enabling scientists worldwide to harness the power of Platinum and drive groundbreaking discoveries."
  • This strategic agreement marks another milestone in Quantum-Si's efforts to unleash the power of proteomics in every lab, everywhere.
  • It follows closely on the heels of the company’s recently announced agreement with ELTA 90, a Bulgarian distributor to distribute Platinum in Southeast Europe.

Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows

Retrieved on: 
Wednesday, November 15, 2023

This agreement between Quantum-Si and ELTA 90 holds immense promise for accelerating scientific research by delivering the game changing tool, Platinum, which interrogates proteins with single-molecule amino acid resolution.

Key Points: 
  • This agreement between Quantum-Si and ELTA 90 holds immense promise for accelerating scientific research by delivering the game changing tool, Platinum, which interrogates proteins with single-molecule amino acid resolution.
  • “We are thrilled to partner with ELTA 90 in this venture.
  • The synergy between Quantum-Si and ELTA 90 represents a major stride toward expanding the field of proteomics,” explained Quantum-Si Chief Executive Officer Jeff Hawkins.
  • We look forward to working with Quantum-Si to unleash the power of next-generation protein sequencing™ in labs throughout Southeast Europe,” expressed Theodor Zamfirov, M.D., Chief Executive Officer of ELTA 90.

Quantum-Si Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the third quarter ended September 30, 2023.
  • For the nine months ended September 30, 2023, the Company recorded revenue of $682,000, gross profit of $310,000, and gross margin of 45%.
  • As of September 30, 2023, cash and cash equivalents and investments in marketable securities were $274.6 million.
  • The Company maintains the expectation that the balance in cash and cash equivalents and investments in marketable securities of $274.6 million as of September 30, 2023 will provide a runway into 2026
    Quantum-Si will host a conference call to discuss its third quarter 2023 financial results on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time.

Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards

Retrieved on: 
Wednesday, November 8, 2023

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has received the “Proteomics Company of the Year” award from the BioTech Breakthrough Awards as part of the program’s 2023 award recipients for its first of a kind protein sequencing instrument.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has received the “Proteomics Company of the Year” award from the BioTech Breakthrough Awards as part of the program’s 2023 award recipients for its first of a kind protein sequencing instrument.
  • “Since the groundbreaking introduction of Platinum™, Quantum-Si has swiftly emerged as an industry trailblazer, galvanizing the scientific community with a pioneering focus on proteomics,” said Quantum-Si Chief Executive Officer Jeff Hawkins.
  • This year, the inclusion of a new awards category in proteomics along with three subcategories, signals the immense progress the proteomics industry has made in 2023.
  • Winners in the various categories are featured online at the Biotech Breakthrough Awards website.

Quantum-Si to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in two upcoming investor conferences:

Key Points: 

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in two upcoming investor conferences: